Document is current
Any future updates will be listed below
-
Authors
Strausz, Satu
Kiiskinen, Tuomo
Broberg, Martin
Ruotsalainen, Sanni
Koskela, Jukka
Bachour, Adel
,
Palotie, Aarno
Palotie, Tuula
Ripatti, Samuli
Ollila, Hanna M.
-
Funding
Funding for this research was provided by:
AstraZeneca UK Ltd (Not applicable)
Merck Sharp & Dohme Corp (Not applicable)
Genentech Inc (Not applicable)
Academy of Finland (309643)
Signe and Ane Gyllenberg foundation (Not applicable)
Yrjö Jahnsson foundation (Not applicable)
Celgene Corporation (Not applicable)
Sigrid Juselius Foundation (Not applicable)
Maze Therapeutics Inc (Not applicable)
Pfizer Inc (Not applicable)
Sydäntutkimussäätiö (Not applicable)
Sanofi US Services Inc (Not applicable)
GlaxoSmithKline (Not applicable)
HUCH research grant (Not applicable)
Instrumentarium science foundation (Not applicable)
Oskar Öfflund foundation (Not applicable)
Biogen MA Inc (Not applicable)
University of Helsinki HiLIFE Fellow and Grand Challenge grants (Not applicable)
Academy of Finland Center of Excellence in Complex Disease Genetics (312062)
Academy of Finland Center of Excellence in Complex Disease Genetics (312074)
Celgene International II Sàrl (Not applicable)
AbbVie Inc (Not applicable)
Business Finland (HUS 4685/31/2016)
Business Finland (UH 4386/31/2016)
Janssen Biotech Inc (Not applicable)
Academy of Finland Covid-19 research funding (Not applicable)
Juho Vainio Foundation (Not applicable)
- License Information
